## Sodium stibogluconate

**Essential medicine status**

### 6. Anti-infective medicines

#### 6.5. Antiprotozoal medicines

##### 6.5.2. Antileishmaniasis medicines

<table>
<thead>
<tr>
<th><strong>Indication</strong></th>
<th>Cutaneous leishmaniasis</th>
</tr>
</thead>
</table>

**INN**  Sodium stibogluconate

**Medicine type**  Chemical agent

**List type**  Core

**Formulations**  Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

**EML status history**
- First added in 1977 ([TRS 615](https://www.who.int/mediacentre/factsheets/series/615/en/))
- Changed in 1979 ([TRS 641](https://www.who.int/mediacentre/factsheets/series/641/en/))
- Changed in 1984 ([TRS 722](https://www.who.int/mediacentre/factsheets/series/722/en/))
- Removed in 1989 ([TRS 796](https://www.who.int/mediacentre/factsheets/series/796/en/))
- Added in 2007 ([TRS 950](https://www.who.int/mediacentre/factsheets/series/950/en/))
- Changed in 2009 ([TRS 958](https://www.who.int/mediacentre/factsheets/series/958/en/))
- Changed in 2023 ([TRS 1049](https://www.who.int/mediacentre/factsheets/series/1049/en/))

**Sex**  All

**Age**  Also recommended for children

**Therapeutic alternatives**  The recommendation is for this specific medicine

**Patent information**  Patents have expired in most jurisdictions

**Wikipedia**  Sodium stibogluconate

**DrugBank**  Sodium stibogluconate

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule